Predictions

Foundayo (orforglipron) receives at least one additional major PBM preferred formulary listing (ESI or OptumRx) by July 31, 2026

CVS Caremark preferred formulary access opened June 1 2026 (major catalyst). ESI (Express Scripts) and OptumRx/UnitedHealth are the two remaining major PBMs without confirmed Foundayo preferred status. ADA June 5-8 physician education + strong ACHIEVE trial data creates commercial pressure for PBM coverage decisions. Lilly is known to negotiate aggressively with PBMs. Story notes no ESI/CVS/OptumRx preferred announcement as of May 27. With CVS now confirmed, competitive pressure on ESI/Optum inc

Eli Lilly reports orforglipron (Foundayo) net revenues exceeding 200 million dollars in its first full quarter of commercialization (Q2 2026 reported approximately July 2026)

Orforglipron approved April 2, 2026. Q2 2026 (April-June) is the first full quarter. Significant launch demand likely given GLP-1 market enthusiasm. Lilly has strong managed care relationships and LillyDirect at 49/month cash pay. Goldman projects 60% of oral GLP-1 market for orforglipron eventually. However, 200M in first full quarter requires rapid formulary access, physician adoption. Launch trajectories for new obesity drugs have been strong (Zepbound reached ~1B in first full quarter). Foun

Vertex Pharmaceuticals Q2 2026 non-GAAP EPS is at least $5.20 (beats $4.85 consensus by at least 7.2%)

Vertex beats EPS consensus in nearly every quarter, typically by 8-15%. Existing prediction: EPS beats $4.85 at p=0.80. An EPS of $5.20 requires +7.2% vs consensus. Journavx Medicare Part D coverage from May 1 adds incremental Q2 revenue. CF franchise continues at high-margin. Reports Aug 3. Calibration: +10pp overall applied to natural 0.62.

Vertex Pharmaceuticals Trikafta/Kaftrio global Q2 2026 net revenue is at least $2.55 billion

Zacks consensus for Trikafta Q2: $2.45B. Vertex is a serial beater across CF franchise; typical Q2 beat is 5-10%. A +4% beat above consensus yields $2.55B. Existing CF composite (all CF drugs combined) prediction >=2.85B at p=0.68, but Trikafta standalone is distinct. Vertex Q2 total FY guidance ~$13B implies ~$3.25B Q2 total including Journavx. Calibration: +10pp applied to natural 0.60.

BMS Cobenfy (xanomeline-trospium) Q2 2026 US net revenue is at least $70 million

Q1 2026 Cobenfy: $56M. Need +25% sequential for $70M. Existing predictions: >=80M at p=0.30 (gen-11/12). Headwind: ARISE Phase 3 adjunctive failure (P=0.11) announced July 2026, creating commercial uncertainty despite EMERGENT indication intact. ADEPT-2 delayed. Formulary access improving but growth may stall. Net +10pp calibration, partial discount for ARISE headwind.

BMS Opdivo (nivolumab) global Q2 2026 net revenue is at least $2.3 billion

Existing predictions bracket: >=2.0B at p=0.65 (gen-9b) and >=2.4B at p=0.62 (gen-4), implying high probability density between $2.3-2.4B. Opdivo Qvantig SC launch adding volume to IV revenues; BMS Q2 2025 Opdivo ~$2.0-2.1B; YoY growth ~15%. Reports before market open today. Net calibration: +10pp overall applied to natural 0.62.

BMS Pomalyst (pomalidomide) Q2 2026 net revenues will be at or below $250 million

Q1 2026 Pomalyst was $513M (-39% YoY). Pomalidomide biosimilar competition accelerating; Zacks Q2 consensus $210M. A steep sequential decline to <=250M requires roughly -51% from Q1 — aggressive but consistent with LOE erosion pace. Probability derived from Zacks consensus of $210M; P(actual <=250M) = ~62% given distribution around consensus; calibration leaves at 0.60.

BMS Yervoy (ipilimumab) Q2 2026 net revenues will be at or above $680 million

Q1 2026 Yervoy was $651M (+4% YoY). Mature CTLA-4 checkpoint; 4.5% sequential growth required to hit $680M. Cornelius: mature blockbuster Q2-at-Q1-actual probability ~40-50%. Opdivo/Yervoy combo remains standard of care in multiple indications. Seasonal/access stable. Base 45% + 10pp undercorrection offset = 48%.

BMS Sotyktu (deucravacitinib) Q2 2026 net revenues will be at or above $80 million

Q1 2026 Sotyktu was $69M (+43% YoY). Drug is still in early ramp phase for TYK2 in psoriasis with no structural LOE drag. Analysts flag increasing demand. A 16% sequential step would reach $80M. Base 50% + 10pp calibration undercorrection adjustment = 52%. Access/prior-auth friction caps upside.

BMS Revlimid (lenalidomide) Q2 2026 net product revenue falls to at most $100M (extreme year-3 biosimilar erosion bracket; gen-15 existing prediction is <$200M at p=0.55)

Revlimid lost exclusivity in 2022 with volume-gated generic entry. By year 3 (2025-2026), branded revenue typically falls 80-90%+ from peak. Original peak ~$800M/Q; year 3 Q2 2026 could range $80-200M. Gen-15 predicts <$200M at p=0.55 suggesting median ~$150-175M. <=100M requires deeper-than-median erosion. BMS Q2 2025 Revlimid was ~$300M (by reference to gen-4 <$280M at p=0.60 implying Q1 2026 above $280M). Calibration +10pp applied; base estimate 0.25, net 0.32.

Bristol-Myers Squibb Q2 2026 total net product revenues equal or exceed $12.0 billion (reported July 30 2026)

BMS FY2026 guidance $46-47.5B; Q1 approximately $11.9B per press release April 2026. Company beat EPS in each of last 4 quarters. Analyst Q2 EPS consensus $1.61 (+10.3% YoY). Growth from Camzyos (+97% Q1 YoY), Cobenfy (+107% QoQ), Breyanzi (+101% YoY), Reblozyl partially offsetting Eliquis/Revlimid generic erosion. $12.0B is slight acceleration from Q1 consistent with FY trajectory midpoint. Applied +10pp for overall underconfident correction; uncertainty about exact consensus revenue threshold.

Gilead Sciences raises FY 2026 total revenue guidance again above current $29.4-29.8B range at Q2 July 30 earnings

Gilead raised FY 2026 revenue guidance by $400M at Q1 to $29.4-29.8B. A second sequential raise at Q2 would require HIV franchise to be significantly tracking above raised range. Biktarvy Q1 $3.4B annualized is approximately $13.6B vs FY guidance approximately $13.5B, running close to ceiling. Yeztugo lenacapavir PrEP adds incremental revenue and BIC/LEN PDUFA Aug 27 could signal HIV portfolio strength. Calibration +11pp from base ~40%.

Gilead Sciences Q2 2026 total product revenue exceeds $7.1B when reported July 30

Gilead Q1 2026 total revenue approximately $7.0B based on raised FY guidance of $29.4-29.8B implying ~$7.35B/quarter average. HIV franchise on 8% FY growth track, Yeztugo (lenacapavir for PrEP) contributing incremental revenue. >$7.1B is a modest sequential step. Calibration +11pp from base ~52%.

Gilead Biktarvy Q2 2026 net product revenue exceeds $3.5B when reported July 30

Biktarvy Q1 2026 was $3.4B (+7% YoY), maintaining >52% US HIV market share. Gilead guided FY HIV growth +8%. $3.5B requires approximately 3% sequential growth, consistent with steady market penetration. No significant competitive threat before BIC/LEN PDUFA Aug 27. Gilead raised FY guidance by $400M at Q1. Calibration +11pp from base ~54%.

Bristol Myers Squibb Cobenfy Q2 2026 net revenue exceeds $100M when reported July 30

Cobenfy (xanomeline-trospium) Q1 2026 net revenue was $56M (+107% YoY), fastest-growing BMS launch. Remote parallel run predicted >$75M at p=0.58; this prediction tests the higher $100M threshold. Doubling sequentially from $56M to >$100M is aggressive but consistent with strong new-to-brand prescription trends in a large unmet-need indication. Key risk: reimbursement hurdles. Calibration +11pp applied to base ~43%.

Bristol Myers Squibb Q2 2026 total revenues equal or exceed its Q1 2026 total revenues (sequential non-decline)

Remote 04:30Z run predicts BMS Q2 beats analyst consensus (p=0.67). This question asks different: can BMS hold Q2 revenues above Q1 levels. BMS in structural LOE transition (Revlimid generics deepening, Eliquis approaching). Cornelius LOE-phase rule: P(Q2 >= Q1 actual) = 30-40%, not 65-70%. Growth portfolio (Camzyos $314M, Cobenfy $56M) partially offsets but Revlimid erosion likely dominates. Calibration +11pp raised from 30%.

At least one new large-cap pharma or biotech acquisition deal valued above $5 billion USD announced publicly in May 2026

Q1-Q2 2026 has been a very active M&A period (Biogen-Apellis $9.6B, Lilly-Kelonia $7B, Neurocrine-Soleno $2.9B, Gilead-Arcellx $7.8B, Gilead-Tubulis $5B). Base rate for at least one $5B+ deal per month in current environment is ~50-60%. Patent cliff pressures on large pharma maintain pipeline acquisition incentives.

Novo Nordisk oral semaglutide (Wegovy pill for obesity) maintains higher weekly total prescriptions than Eli Lilly Foundayo (orforglipron) in every week of May 2026

Oral Wegovy launched January 2026 with 3,071 Rx week 1, now 4+ months ahead. Foundayo week 2 already 3,707 TRx, launching faster than Wegovy pill did. If Foundayo hits 7,000+ by week 4 of May and Wegovy pill is ~8,000+, oral semaglutide stays ahead. But if Foundayo ramp accelerates and oral Wegovy plateaus (as expected given market saturation), Foundayo could overtake by mid-May. Price freeze for oral Wegovy through Aug 31 helps Novo maintain early advantage. Genuinely close race. P=0.52 slight

Novo Nordisk oral Wegovy (semaglutide 4mg) weekly total prescriptions (TRx) will remain above 100,000 per week in the US through end of May 2026

Oral Wegovy launched January 2026, reaching approximately 600K+ prescriptions by March (implying ~200K+/week at peak). Foundayo competition launched April 1 may divert some new patient starts. Novo's price freeze through August 31 (matching Foundayo 49/month self-pay) helps retention. Compounding pharmacy restrictions (FDA requiring cessation by May 22) could actually benefit branded Wegovy. 100K/week is well below the ~200K/week trajectory, suggesting significant buffer. P=0.62.

Gilead-Arcellx acquisition transaction fully closes (any structure including compelled short-form merger) by May 31, 2026

All regulatory approvals obtained. Even if tender fails 50% threshold today, Gilead can pursue compelled short-form merger. However low tender rate suggests possible holdouts requiring additional extension. Timeline: another extension or court-ordered process may push past May 31. Cornelius: 'deal closes eventually' vs 'closes by THIS deadline' require separate base rates. Deadline-specific P=0.62.